First patient dosed in clinical trial of ICP-B794 in China
Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, “B7-H3 is specifically expressed in a wide range of solid tumors. ICP-B794 was developed from our proprietary ADC platform, and its differentiated design offers potential to provide precise treatment options for cancer patients. We will continue to expand our portfolio with multiple ADC candidates and bring more hope to cancer patients worldwide.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.